Details for Patent: 9,387,191

Which drugs does patent 9,387,191 protect, and when does it expire?

Patent 9,387,191 protects AURYXIA and is included in one NDA.

This patent has thirty-five patent family members in twelve countries.

Summary for Patent: 9,387,191

Title:	Ferric citrate dosage forms
Abstract:	Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).
Inventor(s):	Le; Henry Trong (Englewood Cliffs, NJ)
Assignee:	Keryx Biopharmaceuticals, Inc. (New York, NY)
Application Number:	13/255,326
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,387,191
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 9,387,191

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Keryx Biopharms	AURYXIA	ferric citrate	TABLET;ORAL	205874-001	Sep 5, 2014		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 9,387,191

PCT Information
PCT Filed	July 21, 2010	PCT Application Number:	PCT/US2010/042788
PCT Publication Date:	January 27, 2011	PCT Publication Number:	WO2011/011541

International Family Members for US Patent 9,387,191

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010276242
Brazil	112012001372
Canada	2768656
China	102573807
China	108938585
China	109223724